Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Ependymoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Glioma (540
)
Glioblastoma (234
)
Astrocytoma (74
)
Oligodendroglioma (34
)
Glioma (540
)
Glioblastoma (234
)
Astrocytoma (74
)
Oligodendroglioma (34
)
›
Associations
(8)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601) (NCT03095248)
Phase 2
Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cin...
Suspended
Phase 2
Children's Hospital Medical Center, Cincinnati
Suspended
Last update posted :
06/12/2024
Initiation :
05/08/2017
Primary completion :
06/01/2024
Completion :
06/01/2025
NF2
|
NF2 mutation
|
Koselugo (selumetinib)
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (NCT02359565)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/10/2024
Initiation :
05/22/2015
Primary completion :
12/31/2026
Completion :
12/31/2026
PD-L1 • TMB
|
TMB-H
|
Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors (NCT01445288)
Phase N/A
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase N/A
National Cancer Institute (NCI)
Completed
Last update posted :
06/10/2024
Initiation :
12/05/2006
VEGFA • TNFA
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/06/2024
Initiation :
07/31/2017
Primary completion :
09/30/2027
Completion :
09/30/2027
BRAF
|
Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers (NCT03173950)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
07/13/2017
Primary completion :
04/21/2026
Completion :
04/21/2027
BCOR • FOXR2
|
Opdivo (nivolumab)
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (NCT06161519)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
01/31/2024
Primary completion :
11/14/2028
Completion :
11/14/2033
MYCN
|
MYCN amplification
|
PLX038
Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors (PNOC028) (NCT05887882)
Phase 1
Sabine Mueller, MD, PhD
Sabine Mueller, MD, PhD
Recruiting
Phase 1
Sabine Mueller, MD, PhD
Recruiting
Last update posted :
06/04/2024
Initiation :
05/31/2024
Primary completion :
12/31/2027
Completion :
12/31/2027
TGFB1 • TGFBI
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (NCT03434262)
Phase 1
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Completed
Phase 1
St. Jude Children's Research Hospital
Completed
Last update posted :
05/31/2024
Initiation :
03/05/2018
Primary completion :
09/30/2022
Completion :
05/24/2024
PTCH1
|
PTCH1 mutation
|
Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/21/2024
Initiation :
08/13/2018
Primary completion :
03/31/2023
Completion :
09/22/2024
RB1
|
Ibrance (palbociclib)
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/21/2024
Initiation :
11/28/2017
Primary completion :
09/30/2023
Completion :
10/01/2024
PTEN • TSC2 • TSC1
|
PTEN expression • TSC1 mutation • TSC2 mutation
|
samotolisib (LY3023414)
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/21/2024
Initiation :
08/23/2017
Primary completion :
09/30/2024
Completion :
09/30/2024
NTRK
|
NTRK fusion
|
Vitrakvi (larotrectinib)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/17/2024
Initiation :
11/08/2017
Primary completion :
06/30/2022
Completion :
09/22/2024
BRAF
|
BRAF mutation • BRAF V600
|
Zelboraf (vemurafenib)
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (NCT02101905)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/29/2024
Initiation :
03/13/2014
Primary completion :
10/19/2021
Completion :
10/19/2024
EGFR
|
EGFR amplification
|
lapatinib
Phase I Study of APX005M in Pediatric CNS Tumors (NCT03389802)
Phase 1
Pediatric Brain Tumor Consortium
Pediatric Brain Tumor Consortium
Active, not recruiting
Phase 1
Pediatric Brain Tumor Consortium
Active, not recruiting
Last update posted :
04/08/2024
Initiation :
03/01/2018
Primary completion :
09/30/2023
Completion :
09/30/2024
TMB • CD4
|
sotigalimab (PYX-107)
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children (NCT03043391)
Phase 1
Istari Oncology, Inc.
Istari Oncology, Inc.
Completed
Phase 1
Istari Oncology, Inc.
Completed
Last update posted :
04/08/2024
Initiation :
11/07/2017
Primary completion :
03/23/2022
Completion :
03/23/2022
NF1
|
NF1 mutation
|
lerapolturev (PVS-RIPO)
Molecular-Guided Therapy for Childhood Cancer (NCT02162732)
Phase N/A
Giselle Sholler
Giselle Sholler
Completed
Phase N/A
Giselle Sholler
Completed
Last update posted :
04/05/2024
Initiation :
07/08/2014
Primary completion :
01/18/2024
Completion :
01/18/2024
MYCN
|
MYCN amplification
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma (NCT04903080)
Phase 1
Pediatric Brain Tumor Consortium
Pediatric Brain Tumor Consortium
Recruiting
Phase 1
Pediatric Brain Tumor Consortium
Recruiting
Last update posted :
04/05/2024
Initiation :
07/27/2022
Primary completion :
07/20/2028
Completion :
07/20/2043
HER-2
|
HER-2 positive
|
cyclophosphamide
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases (NCT03796273)
Phase 1
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Recruiting
Phase 1
Wake Forest University Health Sciences
Recruiting
Last update posted :
04/03/2024
Initiation :
03/13/2019
Primary completion :
07/01/2024
Completion :
09/01/2024
KDR • CD24 • POU5F1 • VEGFC
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (NCT04743661)
Phase 2
Pediatric Brain Tumor Consortium
Pediatric Brain Tumor Consortium
Active, not recruiting
Phase 2
Pediatric Brain Tumor Consortium
Active, not recruiting
Last update posted :
03/29/2024
Initiation :
04/04/2022
Primary completion :
10/30/2029
Completion :
10/30/2030
CD276
|
Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous
Study of the Effect of GM-CSF on Macrophages in Ependymoma (NCT04408092)
Phase 1
University of Colorado, Denver
University of Colorado, Denver
Completed
Phase 1
University of Colorado, Denver
Completed
Last update posted :
03/15/2024
Initiation :
06/25/2013
Primary completion :
09/21/2021
Completion :
07/21/2023
AIF1
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors (NCT05835687)
Phase 1
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Recruiting
Phase 1
St. Jude Children's Research Hospital
Recruiting
Last update posted :
03/13/2024
Initiation :
04/27/2023
Primary completion :
03/01/2028
Completion :
03/01/2028
CD276
|
B7-H3 CAR-T
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (NCT04374305)
Phase 2
Scott R. Plotkin, MD, PhD
Scott R. Plotkin, MD, PhD
Recruiting
Phase 2
Scott R. Plotkin, MD, PhD
Recruiting
Last update posted :
03/13/2024
Initiation :
06/20/2020
Primary completion :
12/01/2029
Completion :
12/01/2030
NF2
|
Nerlynx (neratinib) • Alunbrig (brigatinib)
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (NCT02100891)
Phase 2
Monica Thakar
Monica Thakar
Completed
Phase 2
Monica Thakar
Completed
Last update posted :
03/12/2024
Initiation :
03/20/2013
Primary completion :
06/08/2020
Completion :
07/15/2020
HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) (NCT03838042)
Phase 1/2
University Hospital Heidelberg
University Hospital Heidelberg
Recruiting
Phase 1/2
University Hospital Heidelberg
Recruiting
Last update posted :
02/07/2024
Initiation :
05/26/2020
Primary completion :
06/30/2026
Completion :
06/30/2027
PD-L1 • TMB • MYC
|
PD-L1 expression
|
Opdivo (nivolumab) • Jingzhuda (entinostat)
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (NCT01661400)
Phase 1
Washington University School of Medicine
Washington University School of Medicine
Completed
Phase 1
Washington University School of Medicine
Completed
Last update posted :
01/31/2024
Initiation :
10/26/2012
Primary completion :
12/27/2023
Completion :
12/27/2023
CD34
|
cyclophosphamide • thalidomide • cyclophosphamide intravenous
Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma (NCT02774421)
Phase 1
University of Colorado, Denver
University of Colorado, Denver
Recruiting
Phase 1
University of Colorado, Denver
Recruiting
Last update posted :
12/25/2023
Initiation :
12/01/2016
Primary completion :
11/01/2025
Completion :
03/01/2026
CSF2
|
Herceptin (trastuzumab)
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (NCT03500991)
Phase 1
Seattle Children's Hospital
Seattle Children's Hospital
Active, not recruiting
Phase 1
Seattle Children's Hospital
Active, not recruiting
Last update posted :
12/20/2023
Initiation :
07/26/2018
Primary completion :
07/26/2024
Completion :
07/26/2039
HER-2
|
HER-2 positive
|
HER2-Specific CAR T
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (NCT04185038)
Phase 1
Seattle Children's Hospital
Seattle Children's Hospital
Recruiting
Phase 1
Seattle Children's Hospital
Recruiting
Last update posted :
12/20/2023
Initiation :
12/11/2019
Primary completion :
05/01/2026
Completion :
05/01/2041
CD276
|
CD276 expression
|
SCRI-CARB7H3(s)
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (NCT03638167)
Phase 1
Seattle Children's Hospital
Seattle Children's Hospital
Active, not recruiting
Phase 1
Seattle Children's Hospital
Active, not recruiting
Last update posted :
10/27/2023
Initiation :
03/19/2019
Primary completion :
03/01/2025
Completion :
03/01/2040
EGFR
|
EGFR expression • EGFR positive
|
EGFR806-specific CAR T-cell therapy
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer (NCT04521946)
Phase 1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Withdrawn
Phase 1
M.D. Anderson Cancer Center
Withdrawn
Last update posted :
10/04/2023
Initiation :
01/14/2021
Primary completion :
12/20/2022
Completion :
12/20/2022
HLA-DRB1 • HLA-B • HLA-C • KIR2DS2
|
etoposide IV • melphalan • fludarabine IV • thiotepa
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (NCT03152318)
Phase 1
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Recruiting
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
08/08/2023
Initiation :
07/18/2017
Primary completion :
12/01/2024
Completion :
12/01/2025
IDH1
|
IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132
|
cyclophosphamide • CAN-3110
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors (NCT03220646)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/07/2023
Initiation :
07/13/2017
Primary completion :
07/01/2024
Completion :
07/01/2024
EGFR • FGFR
|
IDH wild-type
|
cisplatin • Verzenio (abemaciclib)
Temozolomide and Radiation Therapy in Treating Patients With Gliomas (NCT00114140)
Phase 2
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Completed
Phase 2
Radiation Therapy Oncology Group
Completed
Last update posted :
06/14/2022
Initiation :
01/01/2005
Primary completion :
02/01/2013
Completion :
05/20/2022
MGMT
|
temozolomide
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors (NCT03387020)
Phase 1
Pediatric Brain Tumor Consortium
Pediatric Brain Tumor Consortium
Completed
Phase 1
Pediatric Brain Tumor Consortium
Completed
Last update posted :
08/27/2021
Initiation :
01/13/2018
Primary completion :
04/01/2020
Completion :
04/01/2020
RB1
|
everolimus • Kisqali (ribociclib)
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas (NCT01125046)
Phase 2
Northwestern University
Northwestern University
Completed
Phase 2
Northwestern University
Completed
Last update posted :
01/22/2021
Initiation :
06/17/2010
Primary completion :
03/10/2014
Completion :
12/31/2018
HER-2
|
HER-2 expression • VEGFA expression
|
Avastin (bevacizumab)
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (NCT01331135)
Phase 1
Emory University
Emory University
Completed
Phase 1
Emory University
Completed
Last update posted :
05/29/2020
Initiation :
04/01/2011
Primary completion :
08/09/2017
Completion :
08/09/2017
AFP
|
sirolimus
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors (NCT00994071)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
12/09/2019
Initiation :
09/22/2009
Completion :
03/19/2013
AFP
|
temozolomide • veliparib (ABT-888)
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer (NCT01325207)
Phase 1/2
Northwestern University
Northwestern University
Completed
Phase 1/2
Northwestern University
Completed
Last update posted :
09/26/2019
Initiation :
08/01/2011
Primary completion :
06/20/2016
Completion :
01/20/2019
HER-2
|
HER-2 positive
|
Herceptin (trastuzumab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login